Clinical trials: Glucagon
Glucose Metabolism Disorders
The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D
Delineation of the role of glucagon-like peptide-1 receptor signalling in the glucose-lowering effect of metformin during meal ingestion in patients with type 2 diabetes.
- Trial name
- NCT03246451
- Testing
- Metformin, Saline, Exendin (9-39)
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09
JY09 is a glucagon-like peptide-1 (GLP-1) mimetic generated by genetic fusion of a Exendin-4 dimer to human immunoglobulin Fc. In this Double-blind, randomized, placebo-controlled trial, 41 healthy subjects received placebo or…
- Trial name
- NCT04354090
- Testing
- JY09
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
Smoking Cessation
Exenatide Once Weekly for Smoking Cessation
The purpose of this study is to identify a potential new treatment for smoking cessation.
- Trial name
- NCT02975297
- Testing
- Exenatide, NRT, Counseling
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- The University of Texas Health Science Center, Houston
Type 1 Diabetes
Closed-loop Control of Glucose Levels After Meal Intake in Adults With Type 1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosage based on the sensor's…
- Trial name
- NCT01930097
- Testing
- 14 hours intervention
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Gastric Emptying, Gastroparesis
Gastric Emptying Recovery After GLP-1 RA Cessation
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can delay gastric emptying and may increase residual gastric contents before general anesthesia.
- Conditions
- Gastric Emptying, Gastroparesis, Preoperative Care
- Trial name
- NCT07360262
- Testing
- Preoperative gastric ultrasound
- Where
- 2 sites in South Korea
- Volunteers
- 186 people
- Sponsor
- Wonkwang University Hospital
Cannabis Use Disorder, Cannabis Use Disorders
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo.
- Conditions
- Cannabis Use Disorder, Cannabis Use Disorders, Cannabis Abuse, Cannabis Dependence
- Trial name
- HASHTAG (NCT07523633)
- Testing
- semaglutide
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Laxity; Skin
Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging
The primary objective is to evaluate the safety and efficacy of a topical serum (AGE serum) in improving visible signs of aging (e.g., fine lines, wrinkles, sagging, texture, radiance) on the full face and neck.The study will be…
- Trial name
- NCT07216352
- Testing
- AGE Serum
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
Diabetes
Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance
The study aims to evaluate the elimination and degradation of glucagon in patients with type 2 diabetes compared to matched healthy subjects.
- Trial name
- MCR Glucagon (NCT02475421)
- Testing
- Glucagon
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 2 Diabetes
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
This is a 32-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and the active comparator in patients with type 2 diabetes…
- Trial name
- NCT06739044
- Testing
- Ozempic®, HDG1901
- Where
- China
- Volunteers
- 494 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Overweight and/or Obesity, Weight Management
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity
- Trial name
- NCT07243171
- Testing
- ecnoglutide tablets
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Diabetes Mellitus, Type 2, Insulin Resistance
Treatment of Type 2 Diabetes Mellitus by Duodenal Exclusion Associated With Omentectomy: Clinical and Hormonal Study
Based in a surgery technique studied in a non-obese diabetic mouse model by Rubino and Marescaux(2004), wich reversed diabetes in those animals, we have performed a previous study in human volunteers with type 2 diabetes and…
- Conditions
- Diabetes Mellitus, Type 2, Insulin Resistance, Obesity
- Trial name
- NCT00566215
- Testing
- Duodenal exclusion plus omentectomy, Duodenal exclusion without omentectomy
- Where
- Brazil
- Volunteers
- 6 people
- Sponsor
- University of Campinas, Brazil
Type 2 Diabetes, Type 1 Diabetes
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
Diabetes(both types) are recognized by high levels of glucagon in the circulation. Glucagon is known to increase blood glucose, and might therefore contribute to the respective diseases.
- Trial name
- NCT01507597
- Testing
- Native human Glucagon-like Peptide-1 ( GLP-1(7-36)), NaCl
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Transfusion Dependent Beta Thalassemia
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia
Blood transfusion and iron-chelation therapy have prolonged and improved the quality of life in patients with β-thalassemia. The improvement was mainly due to the decrease in mortality from heart failure Such a treatment…
- Trial name
- NCT07370922
- Testing
- Dulaglutide 0.75Mg/0.5Ml Inj Pen, control group (insulin)
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Obesity
Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response
A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery
- Trial name
- BARIOPTIMISE (NCT03341429)
- Testing
- Liraglutide Pen Injector [Saxenda]
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- University College, London
Type 2 Diabetes Mellitus
How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin.
The study is aimed at Type 2 Diabetics who are taking Metformin, but whose Diabetes remains poorly controlled. There are two additional medications already in use, Glimepiride and Sitagliptin will be compared to assess levels of…
- Trial name
- MSD-GLP1 (NCT00747383)
- Testing
- Glimepiride, Sitagliptin
- Where
- United Kingdom
- Volunteers
- 74 people
- Sponsor
- The Royal Bournemouth Hospital
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to examine the effect of NNC 90-1170 on the hypoglycaemic counterregulation in subjects with type 2 diabetes.
- Trial name
- NCT01509742
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Novo Nordisk A/S
Hyperglycemia Drug Induced
A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib
REMD-477 (Volagidemab) is a human anti-glucagon receptor antibody. Its proposed mechanism of action in controlling hyperglycemia is by blocking glucagon receptor (GCGR) signaling.
- Trial name
- NCT04253223
- Testing
- REMD-477
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Duke University
Overweight or Obesity
Healthy Living BEYOND Weight Study
The Healthy Living BEYOND Weight Study is an observational research study of participants living with overweight and obesity. The principal objectives for this project will be to answer fundamental unanswered questions regarding…
- Trial name
- NCT07075341
- Testing
- None - Observational study
- Where
- United States
- Volunteers
- 1,000,000 people
- Sponsor
- American Heart Association
Type 1 Diabetes
Closed-Loop Glucagon Administration For Hypoglycemia Treatment
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers glucagon only can prevent or treat hypoglycemia vs. usual care for people with type 1 diabetes > 21 years old.
- Trial name
- NCT02181127
- Testing
- Glucagon-only Bionic Pancreas
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
End Stage Renal Disease
Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).
A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production and plasma glucagon levels in patients with end-stage renal disease (ESRD)
- Trial name
- NCT03713190
- Testing
- Empagliflozin
- Where
- Italy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Pisa